{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Stimulation+in+Lab&page=7", "query": { "intervention": "Stimulation in Lab", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 301, "total_pages": 31, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Stimulation+in+Lab&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Stimulation+in+Lab&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T15:36:30.384Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00389818", "title": "Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "pegylated liposomal doxorubicin hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "AIDS Malignancy Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 43, "start_date": "2007-01", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2018-06-06", "last_synced_at": "2026-10-20T15:36:30.384Z", "location_count": 14, "location_summary": "La Jolla, California • Los Angeles, California • Miami, Florida + 9 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00389818" }, { "nct_id": "NCT00003958", "title": "Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Adult Malignant Mesenchymoma", "Adult Rhabdomyosarcoma", "Alveolar Childhood Rhabdomyosarcoma", "Childhood Malignant Mesenchymoma", "Embryonal Childhood Rhabdomyosarcoma", "Embryonal-botryoid Childhood Rhabdomyosarcoma", "Nonmetastatic Childhood Soft Tissue Sarcoma", "Previously Untreated Childhood Rhabdomyosarcoma", "Stage I Adult Soft Tissue Sarcoma", "Stage II Adult Soft Tissue Sarcoma", "Stage III Adult Soft Tissue Sarcoma" ], "interventions": [ { "name": "dactinomycin", "type": "BIOLOGICAL" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "topotecan hydrochloride", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION", "OTHER" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "49 Years", "sex": "ALL", "summary": "Up to 49 Years" }, "enrollment_count": 702, "start_date": "2002-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-17", "last_synced_at": "2026-10-20T15:36:30.384Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003958" }, { "nct_id": "NCT00569296", "title": "Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "EGFRBi-armed autologous activated T cells", "type": "BIOLOGICAL" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Roger Williams Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2007-11", "completion_date": "2015-03", "has_results": false, "last_update_posted_date": "2015-03-25", "last_synced_at": "2026-10-20T15:36:30.384Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT00569296" }, { "nct_id": "NCT01536054", "title": "Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Fallopian Tube Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Primary Peritoneal Cavity Cancer", "Stage IIA Fallopian Tube Cancer", "Stage IIA Ovarian Epithelial Cancer", "Stage IIA Primary Peritoneal Cavity Cancer", "Stage IIB Fallopian Tube Cancer", "Stage IIB Ovarian Epithelial Cancer", "Stage IIB Primary Peritoneal Cavity Cancer", "Stage IIC Fallopian Tube Cancer", "Stage IIC Ovarian Epithelial Cancer", "Stage IIC Primary Peritoneal Cavity Cancer", "Stage IIIA Fallopian Tube Cancer", "Stage IIIA Ovarian Epithelial Cancer", "Stage IIIA Primary Peritoneal Cavity Cancer", "Stage IIIB Fallopian Tube Cancer", "Stage IIIB Ovarian Epithelial Cancer", "Stage IIIB Primary Peritoneal Cavity Cancer", "Stage IIIC Fallopian Tube Cancer", "Stage IIIC Ovarian Epithelial Cancer", "Stage IIIC Primary Peritoneal Cavity Cancer", "Stage IV Fallopian Tube Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "sirolimus", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 7, "start_date": "2012-08-20", "completion_date": "2015-04-21", "has_results": false, "last_update_posted_date": "2020-03-27", "last_synced_at": "2026-10-20T15:36:30.384Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01536054" }, { "nct_id": "NCT03670966", "title": "211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia in Remission", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Acute Myeloid Leukemia in Remission", "Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndrome With Excess Blasts", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia", "Recurrent Mixed Phenotype Acute Leukemia", "Refractory Mixed Phenotype Acute Leukemia", "Hematopoietic and Lymphoid Cell Neoplasm" ], "interventions": [ { "name": "Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Bone Marrow Transplantation", "type": "PROCEDURE" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Recombinant Granulocyte Colony-Stimulating Factor", "type": "BIOLOGICAL" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 30, "start_date": "2019-07-10", "completion_date": "2029-10-20", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-10-20T15:36:30.384Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03670966" }, { "nct_id": "NCT01688856", "title": "Contralaterally Controlled FES of Arm & Hand for Subacute Stroke Rehabilitation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stroke", "Hemiparesis", "Hemiplegia" ], "interventions": [ { "name": "Electrical Stimulator", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "MetroHealth Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "21 Years to 80 Years" }, "enrollment_count": 67, "start_date": "2013-01", "completion_date": "2018-08-31", "has_results": true, "last_update_posted_date": "2020-01-09", "last_synced_at": "2026-10-20T15:36:30.384Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01688856" }, { "nct_id": "NCT02502786", "title": "Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Osteosarcoma" ], "interventions": [ { "name": "humanized anti-GD2 antibody", "type": "BIOLOGICAL" }, { "name": "GM-CSF", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Months", "maximum_age": "40 Years", "sex": "ALL", "summary": "13 Months to 40 Years" }, "enrollment_count": 46, "start_date": "2015-07", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-10-20T15:36:30.384Z", "location_count": 3, "location_summary": "Los Angeles, California • New York, New York • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02502786" }, { "nct_id": "NCT02367170", "title": "Project 4A: Inspiratory Muscle Training and Diaphragm Strength", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sepsis" ], "interventions": [ { "name": "Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure", "type": "PROCEDURE" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Volitional Measurement of Maximal Inspiratory Pressure (MIP)", "type": "PROCEDURE" }, { "name": "Inspiratory Muscle Strength Training (IMST)", "type": "DEVICE" }, { "name": "SHAM Inspiratory Muscle Strength Training (IMST)", "type": "DEVICE" }, { "name": "Diaphragm thickness measurement", "type": "PROCEDURE" }, { "name": "Blood and Urine samples", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "DEVICE", "OTHER" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2015-03", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2018-05-07", "last_synced_at": "2026-10-20T15:36:30.384Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02367170" }, { "nct_id": "NCT05866003", "title": "tDCS + CCFES-mediated Functional Task Practice for Post-stroke Upper Extremity Hemiplegia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stroke", "Upper Extremity Paresis", "Hemiplegia" ], "interventions": [ { "name": "Active conventional tDCS montage plus CCFES", "type": "DEVICE" }, { "name": "Active unconventional tDCS montage plus CCFES", "type": "DEVICE" }, { "name": "Sham tDCS plus CCFES", "type": "DEVICE" }, { "name": "CCFES with Occupational Therapy", "type": "BEHAVIORAL" } ], "intervention_types": [ "DEVICE", "BEHAVIORAL" ], "sponsor": "MetroHealth Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "21 Years to 90 Years" }, "enrollment_count": 63, "start_date": "2023-07-01", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2025-09-29", "last_synced_at": "2026-10-20T15:36:30.384Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05866003" }, { "nct_id": "NCT06257056", "title": "Deep Brain Stimulation for Psychosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Treatment-Refractory Schizophrenia" ], "interventions": [ { "name": "Abbott Laboratories Infinity™ implantable deep brain stimulation system", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Bradley Lega", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "22 Years to 70 Years" }, "enrollment_count": 10, "start_date": "2024-04-03", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-10-20T15:36:30.384Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06257056" } ] }